NovoCure Ltd

NVCRSEC EDGAR

Surgical & Medical Instruments & ApparatusCIK: 1645113

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$509.3M	$537.8M	$535.0M	$101.8M	$73.3M
Cost of Revenue	$128.3M	$114.9M	$114.9M	$106.5M	$88.6M
Gross Profit	$381.1M	$423.0M	$420.2M	$77.3M	$53.5M
Research and Development Expense	$223.1M	$206.1M	$201.3M	$132.0M	$79.0M
Operating Expenses	$613.9M	$512.5M	$464.5M	$357.5M	$263.6M
Operating Income (Loss)	-$232.9M	-$89.5M	-$44.3M	-$3.4M	-$6.1M
Interest Expense	$4.9M	$8.1M	$8.8M	$18.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.2B	$1.1B	$1.2B	$1.1B	$1.1B
Assets, Current	$1.1B	$1.0B	$1.1B	$1.1B	$999.4M
Cash and Cash Equivalents, at Carrying Value	$240.8M	$115.3M	$208.8M	$208.8M	$234.7M
Accounts Receivable, after Allowance for Credit Loss, Current	$74.2M	$61.2M	$86.3M	$93.6M	$96.7M
Inventory, Net	$35.1M	$38.2M	$29.4M	$24.4M	$27.4M
Liabilities	$880.6M	$783.6M	$750.5M	$729.0M	$575.5M
Liabilities, Current	$756.4M	$179.1M	$158.8M	$142.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$73.3M	$30.8M	$82.8M	$99.1M	$26.6M
Net Cash Provided by (Used in) Investing Activities	$184.1M	-$140.0M	-$144.8M	-$472.8M	-$51.7M
Net Cash Provided by (Used in) Financing Activities	$15.8M	$15.5M	$25.7M	$440.2M	$61.7M
Payments to Acquire Property, Plant, and Equipment	$27.1M	$21.4M	$24.2M	$15.0M	$10.5M
Payments of Dividends	—	—	—	—	—
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)